Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Fluoxetine versus other types of pharmacotherapy for depression

This is not the most recent version

Information

DOI:
https://doi.org/10.1002/14651858.CD004185.pub2Copy DOI
Database:
  1. Cochrane Database of Systematic Reviews
Version published:
  1. 19 October 2005see what's new
Type:
  1. Intervention
Stage:
  1. Review
Cochrane Editorial Group:
  1. Cochrane Common Mental Disorders Group

Copyright:
  1. Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Article metrics

Altmetric:

Cited by:

Cited 0 times via Crossref Cited-by Linking

Collapse

Authors

  • Andrea Cipriani

    Correspondence to: Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy

    [email protected]

    [email protected]

  • Paulo Brambilla

    Department of Psychological Medicine, University of Udine, Udine, Italy

  • Toshi A Furukawa

    Department of Psychiatry & Cognitive‐Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

  • John Geddes

    Department of Psychiatry, University of Oxford/Warneford Hospital, Oxford, UK

  • Manuela Gregis

    Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy

  • Matthew Hotopf

    Department of Psychological Medicine, The Institute of Psychiatry, London, UK

  • Lara Malvini

    Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy

  • Corrado Barbui

    Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Verona, Italy

Contributions of authors

AC, CB and PB collected the data; AC, CB, TF and JG run the analysis; AC and CB drafted the paper; MG, LM, MH, JG and TF revised the manuscript.

Sources of support

Internal sources

  • Department of Medicine and Public Health, Section of Psychiatry and Clinical Psychology, University of Verona, Italy.

  • Department of Psychiatry, University of Oxford, UK.

External sources

  • No sources of support supplied

Declarations of interest

available in

AC, CB, LM, MG, MH and PB: none declared.
TAF has received fees for speaking and also several research grants from pharmaceutical companies that market antidepressants (paroxetine, fluvoxamine, milnacipran, trazodone, mianserin), antipsychotics (risperidone, olanzapine, quetiapine), nootropics (donepezil) and anxiolytics (loflazepate).
JG has received research funding and support from Sanofi‐Aventis and GlaxoSmithKline and is currently in discussion with several other companies that manufacture SSRIs about collaboration on planned independent trials and systematic reviews.

Acknowledgements

available in

We would like to thank the CCDAN Editorial Team for their support, information and advice.

Version history

Published

Title

Stage

Authors

Version

2013 Jul 17

Fluoxetine versus other types of pharmacotherapy for depression

Review

Laura R Magni, Marianna Purgato, Chiara Gastaldon, Davide Papola, Toshi A Furukawa, Andrea Cipriani, Corrado Barbui

https://doi.org/10.1002/14651858.CD004185.pub3

2005 Oct 19

Fluoxetine versus other types of pharmacotherapy for depression

Review

Andrea Cipriani, Paulo Brambilla, Toshi A Furukawa, John Geddes, Manuela Gregis, Matthew Hotopf, Lara Malvini, Corrado Barbui

https://doi.org/10.1002/14651858.CD004185.pub2

2003 Apr 22

Fluoxetine versus other types of pharmacotherapy for depression

Protocol

Andrea Cipriani, P Brambilla, Corrado Barbui, Matthew Hotopf, B Brambilla

https://doi.org/10.1002/14651858.CD004185

Notes

The searches for this review were repeated using the updated CCDANCTR‐Studies register just prior to publication. These additional searches identified a number of new references that the authors had not yet included. These references have been placed in the Awaiting Assessment section and, if appropriate, will be included in a review update to be published in Issue 2, 2008.